Related Experiment Videos
Sulphonamide as hemolysis-promoting factor in uremia
Scandinavian Journal of Urology and Nephrology
|January 1, 1980
Summary
Uremic patients treated with sulphonamides for urinary tract infections experienced hemolysis due to a defect in the hexose monophosphate (HMP) shunt pathway, making them susceptible to oxidant drugs.
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Background:
- Urinary tract infections are common in uremic patients.
- Sulphonamides are frequently prescribed for urinary tract infections.
Purpose of the Study:
- To investigate the incidence of hemolysis in uremic patients treated with sulphonamides.
- To identify the underlying mechanism of drug-induced hemolysis in this population.
Main Methods:
- Observational study of 39 uremic patients with urinary tract infections.
- Treatment with sulphonamides.
- Monitoring for hemolysis and presence of Heinz-bodies.
Main Results:
- Nine out of 39 patients (23%) developed hemolysis.
- All cases showed the presence of Heinz-bodies.
- Uremic patients exhibited a defect in the hexose monophosphate (HMP) metabolic pathway.
Conclusions:
- Sulphonamide treatment can induce hemolysis in uremic patients.
- A defective HMP pathway in uremia increases susceptibility to oxidant drug-induced hemolysis.